ODI-2001 / Odimma - LARVOL DELTA

ODI-2001, a personalized combinatorial immunotherapy shows antitumoral activity across different syngeneic mice tumor models, including 4T1 (SITC 2024) - "Ethics Approval All experiments performed minimized the number of animals using the adequate statistical method and their suffering. All experiments were approved by the local Ethics Committee and performed in a approved animal facility."

Preclinical • Breast Cancer • Colon Cancer • Colorectal Cancer • Melanoma • Oncology • Solid Tumor

ODI-2001, a personalized combinatorial immunotherapy shows antitumoral activity across different syngeneic mice tumor models, including 4T1 (SITC 2024) - "Ethics Approval All experiments performed minimized the number of animals using the adequate statistical method and their suffering. All experiments were approved by the local Ethics Committee and performed in a approved animal facility."

Preclinical • Breast Cancer • Colon Cancer • Colorectal Cancer • Melanoma • Oncology • Solid Tumor

ODI-2001, a personalized combinatorial immunotherapy shows antitumoral activity across different syngeneic mice tumor models, including 4T1 (ESMO 2024) - "This data demonstrate the significant activity of ODI-2001 as an immunization platform across preclinical cancer models, both in monotherapy and combined with anti-PD1. ODI-2001 represents a promising option to enhance cancer-specific immune responses, potentially increasing the proportion of patients responding to immunotherapy treatments. Based on this data, a phase I with ODI-2001 in advanced solid tumors is under preparation."

Preclinical • Breast Cancer • Colon Cancer • Colorectal Cancer • Melanoma • Oncology • Solid Tumor

Combining the potency of a neoantigen-expressing DNA vector, an anti-CTLA-4 antibody, and an attenuated poxvirus in a personalized immunization platform: Preclinical studies of ODI-2001. (ASCO 2024) - "These data demonstrate a significant antitumoral activity of ODI-2001 as a neoantigen immunization platform across different preclinical cancer models, both in monotherapy and combined with anti-PD1. ODI-2001 represents a promising option to induce de novo cancer-specific immune responses, potentially increasing the proportion of patients responding to immunotherapy treatments. Based on this preclinical program a phase I with ODI-2001 in patients with advanced colorectal carcinoma is currently under preparation."

Preclinical • Tumor-specific neoantigens • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Melanoma • Oncology • Solid Tumor • CD8

Odimma Therapeutics Secures €2 Million to Complete the Preparation of Its First-in-Man Clinical Trial (Businesswire) - "Odimma Therapeutics...announces a seed fundraising of €2 million in order to secure the preparation on its First-in-Man clinical trial with ODI-2001, an innovative first-in-class personalized immunotherapy against cancer...The current activities are focused on the preparation of the Phase I clinical trial in patients with advanced solid tumors. "

Financing • New P1 trial • Oncology • Solid Tumor

ABL AND ODIMMA THERAPEUTICS JOIN FORCES IN PERSONALIZED CANCER IMMUNOTHERAPY (Yahoo Finance) - "ABL Europe...and Odimma Therapeutics...announced that they have signed a development agreement. ABL will manufacture the viral component of Odimma's innovative and proprietary immunization platform ODI-2001. The viral component present in ODI-2001 plays the role of both a strong immune adjuvant and of a carrier for the DNA vector expressing personalized neoantigens. The GMP grade material produced by ABL will support clinical trials and early commercialization....'The production of our viral component is the first pharmaceutical step in the development of ODI-2001, our personalized cancer immunotherapy ready to enter into clinic.'"

Licensing / partnership • Oncology